PPD Named ‘Best Vaccine CRO of the Year’ in Asia-Pacific
PPD was awarded the title of “Best Vaccine CRO of the Year” at the 2021 Asia-Pacific Vaccine Excellence Awards due to its significant contributions to vaccine development in the region. The accolade highlights PPD's performance in innovation, quality delivery, and efficacy within the contract research organization sector. The award was accepted at the Vaccine World Asia Congress 2021, which gathered key stakeholders in the vaccine industry. PPD continues to enhance its presence in the Asia-Pacific, expanding operations and offering various services for clinical trials and vaccine development.
- Recognized as 'Best Vaccine CRO of the Year' at 2021 Asia-Pacific Vaccine Excellence Awards.
- Strong focus on innovation and process optimization in vaccine development.
- Expansion in APAC, with operations and a new multipurpose laboratory in Suzhou, China.
- None.
The award recognizes the contract research organization (CRO) operating within
PPD accepted the award during a virtual ceremony at the third annual
“This vaccine award further exemplifies PPD’s commitment to provide effective site management and ensure quality delivery, which has contributed to our industry reputation as a global leader,” said
PPD continues to expand in APAC to serve local and global customers, with operations across the region. PPD provides a broad range of Phase I-IV services in APAC, including clinical monitoring, project management, regulatory affairs, pharmacovigilance, data management and patient recruitment.
Earlier this year, PPD opened its new multipurpose laboratory in
About PPD
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With more than 30,000 professionals worldwide, PPD has conducted clinical trials in more than 100 countries to help customers deliver life-changing therapies to improve health. We apply innovative technologies, therapeutic expertise and a firm commitment to quality to bend the cost and time curve of drug development and optimize value. For more information, visit www.ppd.com.
This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; the risks related to the proposed merger of PPD by Thermo Fisher Scientific Inc.; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005594/en/
PPD Contacts
Media:
+1 919 456 4425
media@ppd.com
Investors:
+1 910 558 4186
investors@ppd.com
Source:
FAQ
What award did PPD receive in 2021?
Where did the award ceremony for PPD take place?
What services does PPD offer in the Asia-Pacific region?
When did PPD open its new laboratory in Suzhou, China?